Atenolol inhibits the elimination of disopyramide.
The effect of atenolol on the total elimination of disopyramide and its main dealkylated metabolite was studied in 6 patients and 3 volunteers. During administration of 50 mg atenolol b.i.d. the clearance of disopyramide decreased significantly (p less than 0.02) from 1.90 +/- 0.71 (mean +/- SD) to 1.59 +/- 0.68 ml/kg/min, while its half-life, concentration of the metabolite, and the volume of distribution remained unchanged. The reduction in the clearance of disopyramide by atenolol might contribute to the alleged pharmacodynamic interaction between disopyramide and beta-blocking drugs.
D000328:Adult; D000368:Aged; D001262:Atenolol / Q000009:adverse effects* / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy / Q000378:metabolism; D003640:Dealkylation; D004206:Disopyramide / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male
D001262:Atenolol; D004206:Disopyramide